Kite Pharma Company Profile (NASDAQ:KITE)

About Kite Pharma (NASDAQ:KITE)

Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KITE
  • CUSIP: N/A
  • Web:
  • Market Cap: $4.05 billion
  • Outstanding Shares: 56,545,000
Average Prices:
  • 50 Day Moving Avg: $77.72
  • 200 Day Moving Avg: $62.61
  • 52 Week Range: $39.82 - $88.58
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.11
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $26.88 million
  • Price / Sales: 150.74
  • Book Value: $13.83 per share
  • Price / Book: 5.18
  • EBIDTA: ($306,360,000.00)
  • Net Margins: -994.89%
  • Return on Equity: -39.26%
  • Return on Assets: -33.81%
  • Current Ratio: 10.37%
  • Quick Ratio: 10.37%
  • Average Volume: 1.82 million shs.
  • Beta: 2.63
  • Short Ratio: 3.79

Frequently Asked Questions for Kite Pharma (NASDAQ:KITE)

What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

How were Kite Pharma's earnings last quarter?

Kite Pharma Inc (NASDAQ:KITE) posted its earnings results on Monday, May, 8th. The company reported ($1.74) earnings per share for the quarter, missing analysts' consensus estimates of ($1.68) by $0.06. The firm had revenue of $9.80 million for the quarter, compared to analysts' expectations of $8.85 million. Kite Pharma had a negative return on equity of 39.26% and a negative net margin of 994.89%. The firm's revenue was up 92.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.60) EPS. View Kite Pharma's Earnings History.

Where is Kite Pharma's stock going? Where will Kite Pharma's stock price be in 2017?

17 analysts have issued 1 year price targets for Kite Pharma's stock. Their predictions range from $54.00 to $101.00. On average, they anticipate Kite Pharma's stock price to reach $82.00 in the next twelve months. View Analyst Ratings for Kite Pharma.

What are analysts saying about Kite Pharma stock?

Here are some recent quotes from research analysts about Kite Pharma stock:

  • 1. Jefferies Group LLC analysts commented, "The NHS published a mock technology appraisal analysis to assess the value of CAR T therapy and determine a value-based price. The study was conducted for young ALL and determined a price of ??530K ($649K) was justified. We view this price as an upper limit for Axi-Cel pricing, and raise our Axi-Cel price estimate to $300K (prev' $200K). We also decreased WACC to 13% (prev 15%) which was offset by moderating share to drive our new PT of $101." (3/16/2017)
  • 2. Canaccord Genuity analysts commented, "The Kochenderfer study for CAR-19 published in the Journal of Clinical Oncology showed 12 months' median duration of complete response, suggesting positive read-through generally speaking for ZUMA-1. Importantly, 11 of 12 complete responses (CRs) are still ongoing, suggesting the potential for very long-term remission. We believe the CAR-19 data suggest that KTE-C19 is a favorable option for NHL patients with few, if any, other treatment options, which may provide long-term potentially curative benefit." (3/15/2017)
  • 3. Cowen and Company analysts commented, "In conjunction with Cowen's 37th Annual Health Care Conference, we hosted an investor dinner with Kite Pharma's Chairman and CEO Arie Belldegrun, COO Cynthia Butitta, EVR of R&D David Chang and COO Shawn Tomasello. Discussion topics included the recently released ZUMA-1 data, commercial preparations of Axi-Cel, and pipeline and platform advancements. KITE remains a top pick." (3/7/2017)
  • 4. According to Zacks Investment Research, "Kite Pharma reported narrower-than-expected loss in the fourth quarter of 2016. Despite announcing a lower-than-expected sales guidance for 2017, shares shot up on positive topline results from a key study evaluating axicabtagene ciloleucel, its experimental CAR-T therapy, for treating aggressive non-Hodgkin lymphoma (NHL). The solid efficacy profile demonstrated by the study furthers Kite’s chances of getting the drug approved this year. Kite Pharma is focused on the development of immuno-oncology treatments and is looking to revolutionize cancer treatments by engaging the body’s own immune system to treat cancer. Immuno-oncology is a hot therapeutic area with huge commercial potential.  Meanwhile, after declining in 2016, its shares are picking up in 2017, outperforming the Biomed/Genetics industry. However, there are several other companies working to bring innovative immuno-oncology treatments to market." (3/2/2017)
  • 5. Wedbush analysts commented, "KITE is poised to complete submission of the first BLA for a CAR-T therapy, but we believe slow adoption of the new treatment modality may blunt its first mover advantage, as CAR-T competition matures and treatment strategies evolve to address safety and efficacy challenges." (2/1/2017)

Are investors shorting Kite Pharma?

Kite Pharma saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 9,225,586 shares, an increase of 1.4% from the April 13th total of 9,096,256 shares. Based on an average daily trading volume, of 888,124 shares, the short-interest ratio is currently 10.4 days.

Who are some of Kite Pharma's key competitors?

Who owns Kite Pharma stock?

Kite Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.30%), BlackRock Inc. (7.22%), Wildcat Capital Management LLC (4.70%), State Street Corp (2.66%), Menora Mivtachim Holdings LTD. (2.86%) and FMR LLC (1.69%). Company insiders that own Kite Pharma stock include Arie Belldegrun, Cynthia M Butitta, David Bonderman, David D Chang, Farah Champsi, Helen Susan Kim, Jeffrey Wiezorek, Marc Better, Margo R Roberts, Paul L Jenkinson, Ran Nussbaum, Rizwana F Sproule, Roy Doumani and Shawn Tomasello. View Institutional Ownership Trends for Kite Pharma.

Who sold Kite Pharma stock? Who is selling Kite Pharma stock?

Kite Pharma's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Frontier Capital Management Co. LLC, Candriam Luxembourg S.C.A., American Century Companies Inc., UBS Asset Management Americas Inc., Pictet Asset Management Ltd., BB Biotech AG and FMR LLC. Company insiders that have sold Kite Pharma stock in the last year include Arie Belldegrun, Cynthia M Butitta, David D Chang, Farah Champsi, Helen Susan Kim, Jeffrey Wiezorek, Roy Doumani and Shawn Tomasello. View Insider Buying and Selling for Kite Pharma.

Who bought Kite Pharma stock? Who is buying Kite Pharma stock?

Kite Pharma's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Vanguard Group Inc., Columbia Wanger Asset Management LLC, Menora Mivtachim Holdings LTD., Dialectic Capital Management LP, Quantitative Investment Management LLC and Pinnacle Associates Ltd.. Company insiders that have bought Kite Pharma stock in the last two years include Arie Belldegrun, David Bonderman, Jeffrey Wiezorek and Paul L Jenkinson. View Insider Buying and Selling for Kite Pharma.

How do I buy Kite Pharma stock?

Shares of Kite Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Kite Pharma stock cost?

One share of Kite Pharma stock can currently be purchased for approximately $71.66.

Analyst Ratings

Consensus Ratings for Kite Pharma (NASDAQ:KITE) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.47)
Consensus Price Target: $82.00 (14.43% upside)

Analysts' Ratings History for Kite Pharma (NASDAQ:KITE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Jefferies Group LLCSet Price TargetBuy$101.00MediumView Rating Details
5/19/2017HC WainwrightReiterated RatingBuy$85.00MediumView Rating Details
5/19/2017BTIG ResearchReiterated RatingNeutralMediumView Rating Details
5/15/2017Raymond James Financial, Inc.DowngradeOutperform -> Mkt PerformN/AView Rating Details
5/9/2017Maxim GroupSet Price TargetBuy$88.00HighView Rating Details
5/9/2017WedbushDowngradeNeutral -> Underperform$60.00 -> $54.00HighView Rating Details
5/9/2017Goldman Sachs Group IncBoost Price TargetBuy$85.00 -> $89.00HighView Rating Details
5/9/2017Cowen and CompanyReiterated RatingNeutral$74.00HighView Rating Details
5/9/2017Canaccord GenuityReiterated RatingBuy$90.00HighView Rating Details
5/9/2017FBR & CoReiterated RatingOutperform -> Outperform$90.00 -> $91.00MediumView Rating Details
4/6/2017Roth CapitalReiterated RatingBuy$93.00HighView Rating Details
3/13/2017Standpoint ResearchDowngradeBuy -> Hold$85.00LowView Rating Details
3/6/2017Royal Bank of CanadaBoost Price TargetOutperform$85.00 -> $95.00N/AView Rating Details
3/3/2017Stifel NicolausDowngradeBuy -> Hold$74.00N/AView Rating Details
3/2/2017Citigroup IncDowngradeBuy -> Neutral$62.00 -> $87.00N/AView Rating Details
2/22/2017Wells Fargo & CoInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
9/27/2016Barclays PLCBoost Price TargetEqual Weight$60.00 -> $65.00N/AView Rating Details
8/9/2016MizuhoSet Price TargetBuy$80.00N/AView Rating Details
3/20/2016SunTrust Banks, Inc.Reiterated RatingBuy$70.00N/AView Rating Details
8/14/2015GuggenheimReiterated RatingBuyN/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Kite Pharma (NASDAQ:KITE)
Earnings by Quarter for Kite Pharma (NASDAQ:KITE)
Earnings History by Quarter for Kite Pharma (NASDAQ:KITE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($1.68)($1.74)$8.85 million$9.80 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.75)($1.70)$5.74 million$4.90 millionViewListenView Earnings Details
11/9/2016Q316($1.68)($1.49)$4.94 million$7.34 millionViewListenView Earnings Details
8/8/2016Q216($1.21)($0.91)$4.86 million$4.80 millionViewN/AView Earnings Details
5/9/2016Q116($1.08)($0.90)$4.61 million$5.10 millionViewN/AView Earnings Details
2/29/2016Q4($0.71)($0.85)$4.54 million$4.89 millionViewListenView Earnings Details
11/12/2015Q315($0.64)($0.63)$4.06 million$5.10 millionViewListenView Earnings Details
8/10/2015Q215($0.41)($0.48)$2.51 million$4.40 millionViewListenView Earnings Details
5/15/2015Q115$1.16($0.36)$19.70 million$2.90 millionViewN/AView Earnings Details
3/26/2015Q414($0.16)($0.33)ViewN/AView Earnings Details
11/14/2014Q314($0.23)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Kite Pharma (NASDAQ:KITE)
2017 EPS Consensus Estimate: ($7.47)
2018 EPS Consensus Estimate: ($7.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($1.79)($1.36)($1.60)
Q2 20175($1.90)($1.53)($1.74)
Q3 20175($2.17)($1.59)($1.97)
Q4 20175($2.36)($1.77)($2.16)
Q1 20181($2.08)($2.08)($2.08)
Q2 20181($1.87)($1.87)($1.87)
Q3 20181($1.91)($1.91)($1.91)
Q4 20181($1.87)($1.87)($1.87)
(Data provided by Zacks Investment Research)


Dividend History for Kite Pharma (NASDAQ:KITE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Kite Pharma (NASDAQ:KITE)
Insider Ownership Percentage: 20.60%
Institutional Ownership Percentage: 80.73%
Insider Trades by Quarter for Kite Pharma (NASDAQ:KITE)
Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)
Insider Trades by Quarter for Kite Pharma (NASDAQ:KITE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2017Paul L. JenkinsonCFOBuy3,450$72.59$250,435.50View SEC Filing  
5/9/2017Arie BelldegrunChairmanBuy17,000$68.57$1,165,690.00View SEC Filing  
5/9/2017David BondermanDirectorBuy50,000$68.94$3,447,000.00View SEC Filing  
5/1/2017David D ChangEVPSell20,000$82.09$1,641,800.00View SEC Filing  
4/28/2017Farah ChampsiDirectorSell19,168$82.75$1,586,152.00View SEC Filing  
4/26/2017Farah ChampsiDirectorSell123,913$82.67$10,243,887.71View SEC Filing  
4/25/2017Cynthia M ButittaCOOSell15,000$81.85$1,227,750.00View SEC Filing  
4/25/2017Farah ChampsiDirectorSell46,783$82.80$3,873,632.40View SEC Filing  
4/24/2017Farah ChampsiDirectorSell25,818$82.34$2,125,854.12View SEC Filing  
4/17/2017Farah ChampsiDirectorSell115,376$82.42$9,509,289.92View SEC Filing  
4/3/2017Cynthia M ButittaCOOSell5,000$81.96$409,800.00View SEC Filing  
4/3/2017Helen Susan KimEVPSell2,400$81.80$196,320.00View SEC Filing  
3/27/2017Cynthia M ButittaCOOSell10,000$77.67$776,700.00View SEC Filing  
3/9/2017Cynthia M ButittaCOOSell21,118$80.78$1,705,912.04View SEC Filing  
3/1/2017Cynthia M ButittaCOOSell38,882$73.46$2,856,271.72View SEC Filing  
3/1/2017Helen Susan KimEVPSell50,300$67.78$3,409,334.00View SEC Filing  
3/1/2017Jeffrey WiezorekSVPSell18,000$75.01$1,350,180.00View SEC Filing  
3/1/2017Roy DoumaniDirectorSell18,800$74.46$1,399,848.00View SEC Filing  
2/27/2017Cynthia M ButittaCOOSell10,000$54.42$544,200.00View SEC Filing  
1/31/2017Cynthia M ButittaCOOSell10,000$50.56$505,600.00View SEC Filing  
1/6/2017Cynthia M ButittaCOOSell10,000$50.13$501,300.00View SEC Filing  
1/6/2017Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
12/20/2016Arie BelldegrunChairmanSell3,493$50.86$177,653.98View SEC Filing  
12/20/2016Cynthia M ButittaCOOSell2,482$50.86$126,234.52View SEC Filing  
12/20/2016David D. ChangEVPSell1,788$50.86$90,937.68View SEC Filing  
12/20/2016Jeffrey WiezorekSVPSell716$50.86$36,415.76View SEC Filing  
12/20/2016Shawn TomaselloInsiderSell4,901$50.86$249,264.86View SEC Filing  
12/1/2016Jeffrey WiezorekSVPSell1,500$50.76$76,140.00View SEC Filing  
11/25/2016Cynthia M ButittaCOOSell10,000$50.40$504,000.00View SEC Filing  
10/3/2016Jeffrey WiezorekSVPSell1,500$54.81$82,215.00View SEC Filing  
9/26/2016Cynthia M ButittaCOOSell10,000$54.13$541,300.00View SEC Filing  
9/1/2016Jeffrey WiezorekSVPSell1,500$58.24$87,360.00View SEC Filing  
8/25/2016Cynthia M. ButittaCOOSell10,000$58.28$582,800.00View SEC Filing  
8/15/2016Helen Susan KimEVPSell35,900$60.27$2,163,693.00View SEC Filing  
8/1/2016Jeffrey WiezorekSVPSell1,500$56.90$85,350.00View SEC Filing  
7/25/2016Cynthia M ButittaCOOSell10,000$50.94$509,400.00View SEC Filing  
7/1/2016Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  
6/27/2016Cynthia M ButittaCOOSell20,000$50.71$1,014,200.00View SEC Filing  
6/6/2016Roy DoumaniDirectorSell10,000$57.91$579,100.00View SEC Filing  
6/1/2016Jeffrey WiezorekSVPSell3,000$50.65$151,950.00View SEC Filing  
4/4/2016Cynthia M ButittaCFOSell10,000$50.00$500,000.00View SEC Filing  
3/15/2016Jeffrey WiezorekSVPSell9,000$44.88$403,920.00View SEC Filing  
3/15/2016Margo R RobertsInsiderSell8,506$45.23$384,726.38View SEC Filing  
3/15/2016Rizwana F SprouleVPSell8,500$45.27$384,795.00View SEC Filing  
3/1/2016Cynthia M. ButittaCFOSell10,000$50.03$500,300.00View SEC Filing  
2/17/2016Margo R. RobertsinsiderSell9,632$45.06$434,017.92View SEC Filing  
2/17/2016Rizwana F. SprouleVPSell9,567$45.08$431,280.36View SEC Filing  
2/12/2016Margo R. RobertsinsiderSell18,750$64.16$1,203,000.00View SEC Filing  
2/2/2016Cynthia M. ButittaCFOSell1,900$50.13$95,247.00View SEC Filing  
2/1/2016Marc BetterVPSell9,000$47.34$426,060.00View SEC Filing  
1/27/2016Cynthia M. ButittaCFOSell8,100$51.62$418,122.00View SEC Filing  
1/19/2016Rizwana F. SprouleVPSell9,567$55.49$530,872.83View SEC Filing  
1/15/2016Jeffrey WiezorekSVPSell9,000$55.26$497,340.00View SEC Filing  
1/15/2016Margo R. RobertsinsiderSell6,145$55.22$339,326.90View SEC Filing  
1/4/2016Marc BetterVPSell9,000$61.53$553,770.00View SEC Filing  
12/28/2015Cynthia M. ButittaCFOSell10,000$61.56$615,600.00View SEC Filing  
11/27/2015Cynthia M. ButittaCFOSell15,000$86.45$1,296,750.00View SEC Filing  
11/16/2015Jeffrey WiezorekSVPSell9,000$78.08$702,720.00View SEC Filing  
11/16/2015Margo R. RobertsinsiderSell6,145$78.16$480,293.20View SEC Filing  
11/16/2015Rizwana F. SprouleVPSell9,567$78.13$747,469.71View SEC Filing  
11/2/2015David D. ChangEVPSell7,700$71.08$547,316.00View SEC Filing  
11/2/2015Marc BetterVPSell9,000$71.07$639,630.00View SEC Filing  
10/27/2015Cynthia M. ButittaCFOSell10,000$69.91$699,100.00View SEC Filing  
10/15/2015Jeffrey WiezorekSVPSell9,000$62.59$563,310.00View SEC Filing  
10/15/2015Margo R. RobertsinsiderSell6,145$62.57$384,492.65View SEC Filing  
10/15/2015Rizwana F. SprouleVPSell9,567$62.58$598,702.86View SEC Filing  
10/1/2015David D. ChangEVPSell7,700$55.11$424,347.00View SEC Filing  
10/1/2015Marc BetterVPSell9,000$54.81$493,290.00View SEC Filing  
9/28/2015Cynthia M. ButittaCFOSell10,000$55.87$558,700.00View SEC Filing  
9/15/2015Margo R. RobertsinsiderSell6,145$64.33$395,307.85View SEC Filing  
9/15/2015Rizwana F. SprouleVPSell9,567$64.36$615,732.12View SEC Filing  
9/8/2015David D. ChangEVPSell7,700$55.00$423,500.00View SEC Filing  
9/1/2015Marc BetterVPSell9,000$51.81$466,290.00View SEC Filing  
8/27/2015Cynthia M. ButittaCFOSell10,000$53.62$536,200.00View SEC Filing  
8/17/2015Jeffrey WiezorekVPSell9,000$60.87$547,830.00View SEC Filing  
8/17/2015Margo R RobertsInsiderSell6,145$60.90$374,230.50View SEC Filing  
7/1/2015David D ChangEVPSell7,700$61.92$476,784.00View SEC Filing  
7/1/2015Marc BetterVPSell9,000$61.90$557,100.00View SEC Filing  
6/29/2015Cynthia M ButittaCFOSell10,000$59.65$596,500.00View SEC Filing  
6/25/2015Jeffrey WiezorekVPBuy4,000$17.00$68,000.00View SEC Filing  
6/15/2015David D ChangEVPSell7,700$56.98$438,746.00View SEC Filing  
6/15/2015Margo R RobertsInsiderSell8,625$56.99$491,538.75View SEC Filing  
6/15/2015Rizwana F SprouleVPSell9,567$56.98$545,127.66View SEC Filing  
6/2/2015Ran NussbaumDirectorSell305,434$55.35$16,905,771.90View SEC Filing  
6/1/2015Marc BetterVPSell9,000$54.60$491,400.00View SEC Filing  
6/1/2015Ran NussbaumDirectorSell80,760$55.34$4,469,258.40View SEC Filing  
4/27/2015Cynthia M ButittaCFOSell10,000$59.76$597,600.00View SEC Filing  
3/30/2015Ran NussbaumDirectorSell193,730$60.45$11,710,978.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Kite Pharma (NASDAQ:KITE)
Latest Headlines for Kite Pharma (NASDAQ:KITE)
DateHeadline logoKite Pharma Inc (KITE) Short Interest Update - May 22 at 9:16 PM logoBTIG Research Reiterates Neutral Rating for Kite Pharma Inc (KITE) - May 20 at 12:46 AM logoKite Pharma Inc (KITE) Earns Buy Rating from HC Wainwright - May 19 at 10:54 PM logoKite Pharma Inc (KITE) Given a $101.00 Price Target at Jefferies Group LLC - May 19 at 8:28 PM logoKite Pharma Inc (KITE) Given Average Rating of "Hold" by Brokerages - May 19 at 9:01 AM logoKite Pharma (KITE) Announces Presentations on Its Lead CAR-T Therapy Development Program at ASCO - May 17 at 11:09 PM logoKite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting - May 17 at 6:08 PM logoNewman Ferrara LLP Announces Corporate Governance Investigation of Kite Pharma Inc. - Business Wire (press release) - May 16 at 5:59 PM logoNewman Ferrara LLP Announces Corporate Governance Investigation of Kite Pharma Inc. - May 16 at 10:51 AM logoKite Pharma, Inc. – Value Analysis (NASDAQ:KITE) : May 11, 2017 - May 11 at 11:40 PM logoQ2 2017 Earnings Estimate for Kite Pharma Inc Issued By Jefferies Group (KITE) - May 11 at 8:30 AM logoKite Pharma Inc to Post Q2 2017 Earnings of ($1.70) Per Share, FBR & Co Forecasts (KITE) - May 11 at 8:30 AM logoQ2 2017 EPS Estimates for Kite Pharma Inc (KITE) Lifted by Wedbush - May 11 at 8:30 AM logoKite Pharma Inc (KITE) CFO Purchases $250,435.50 in Stock - May 10 at 11:26 PM logoEquities Analysts Set Expectations for Kite Pharma Inc's FY2020 Earnings (KITE) - May 10 at 3:38 PM logoKite Pharma Inc Expected to Post FY2019 Earnings of ($5.52) Per Share (KITE) - May 10 at 2:54 PM logoKite Pharma Inc to Post FY2018 Earnings of ($5.18) Per Share, SunTrust Banks Forecasts (KITE) - May 10 at 2:12 PM logoQ1 2018 Earnings Forecast for Kite Pharma Inc Issued By Wedbush (KITE) - May 10 at 1:08 PM logoKite Pharma Inc (KITE) Given a $88.00 Price Target by Maxim Group Analysts - May 10 at 12:16 AM logoInsider Buying: Kite Pharma Inc (KITE) Director Purchases 50,000 Shares of Stock - May 9 at 7:20 PM logoArie Belldegrun Purchases 17,000 Shares of Kite Pharma Inc (KITE) Stock - May 9 at 4:32 PM logoKite Pharma (KITE) Q1 2017 Results - Earnings Call Transcript - May 9 at 12:05 PM logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Kite Pharma, Inc. - May 9 at 12:05 PM logoEdited Transcript of KITE earnings conference call or presentation 8-May-17 12:30pm GMT - May 9 at 12:05 PM logoKite Pharma (KITE) Posts Q1 Loss, Reveals CAR-T Patient Death - May 9 at 12:05 PM logoKite Pharma, Inc. breached its 50 day moving average in a Bearish Manner : KITE-US : May 9, 2017 - May 9 at 12:05 PM logoKite Pharma Inc (KITE) Given Underperform Rating at Wedbush - May 9 at 8:36 AM logoKite Pharma's (KITE) Buy Rating Reaffirmed at Canaccord Genuity - May 9 at 8:16 AM logoCowen and Company Reaffirms Neutral Rating for Kite Pharma Inc (KITE) - May 9 at 8:14 AM logoGoldman Sachs Group Inc Reiterates "Buy" Rating for Kite Pharma Inc (KITE) - May 9 at 8:12 AM logoKite Pharma Breaks Down & Could Close the Gap (KITE) - May 8 at 5:48 PM logoAnalyst: Kite Pharma's CAR-T Patient Death, Stock Selloff Is A Buying Opportunity - May 8 at 5:48 PM logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kite Pharma, Inc. - KITE - May 8 at 5:48 PM logoKite Pharma Breaks Down & Could Close the Gap - May 8 at 5:48 PM logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Kite Pharma, Inc. (KITE) - May 8 at 5:48 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Kite Pharma, Inc. - May 8 at 5:48 PM logoKite Pharma's (KITE) "Mkt Perform" Rating Reiterated at Raymond James Financial, Inc. - May 8 at 5:28 PM logoKite Pharma Inc (KITE) Posts Quarterly Earnings Results, Misses Estimates By $0.69 EPS - May 8 at 2:54 PM logoHere's What's Dragging Kite Pharma Inc. Down Today - May 8 at 1:43 PM logoKite Pharma Inc (KITE) Stock Cracks on Big Q1 Loss, Sales Miss - May 8 at 1:01 PM logoBRIEF-Kite Pharma says one patient in KTE-C19 study died - Reuters - May 8 at 9:27 AM logoKite Pharma, Inc. (KITE) - May 7 at 6:36 PM logoKite Pharma Inc (KITE) EVP David D. Chang Sells 20,000 Shares - May 3 at 10:02 PM logoKite Pharma Inc (KITE) Expected to Announce Earnings of -$1.68 Per Share - May 3 at 8:18 PM logoKite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards? - Yahoo Finance - May 3 at 8:15 PM logoKite Pharma (KITE) Given Coverage Optimism Score of 0.06 - May 3 at 1:04 AM logoNivalis Therapeutics Reports First Quarter 2017 Financial Results - Business Wire (press release) - May 2 at 4:34 PM logoFarah Champsi Sells 19,168 Shares of Kite Pharma Inc (KITE) Stock - May 1 at 9:42 PM logoKite to Report First Quarter 2017 Financial Results on May 8, 2017 - Business Wire (press release) - May 1 at 1:03 PM logoKite to Report First Quarter 2017 Financial Results on May 8, 2017 - May 1 at 1:03 PM



Kite Pharma (KITE) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff